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An inflammatory response has been observed in lung cancer both locally and systemically. The aim of the present 
study was to investigate whether the alveolar compartment was involved in the inflammatory response in non- small 
cell lung carcinoma (NSCLC). Both inflammatory mediators in bronchoalveolar lavage fluid (BALF) and cytokines 
produced by alveolar macrophages (AM) were investigated. Twenty patients with newly detected NSCLC and nine 
control subjects were studied. The patients had not been treated with chemotherapy, radiotherapy or with systemic 
or inhaled corticosteroids. All patients and control subjects were current smokers or stopped smoking recently. BAL 
was performed in the affected lung as well as in the contralateral lung of NSCLC patients, and only unilaterally in 
control subjects. Comparable results were demonstrated for the levels of the inflammatory mediators TNF-a, 
Interleukin (IL)-6, IL-8 both soluble TNF receptors and the soluble adhesion molecules E-selectin and intercellular 
adhesion molecule (ICAM)-l between the affected lung and the contralateral lung in the NSCLC population as well 
as between the NSCLC population and the control subjects. Moreover, no significant differences in cytokine profiles 
of AM were found between AM obtained from the affected lung and from the contralateral lung. Although BAL is 
a useful tool in the diagnostic procedure for NSCLC, the present findings suggest that BAL does not reflect the 
enhanced inflammatory state, as reported in plasma and in the interstitial compartment around the tumour cells in 
NSCLC. 
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Introduction 
Neoplastic diseases induce profound changes in the mono- 
nuclear phagocyte system: both local and systemic inflam- 
matory responses are observed in the presence of the 
tumour (l-7). The local inflammatory response is charac- 
terized by the accumulation of mononuclear cells in stroma 
around the tumour cells (l-7). The presence of intlamma- 
tory cells that produce cytokines such as TNF-a, inter- 
leukin (IL)-6 and IL-8 can be seen as both advantageous 
and harmful for the tumour (8-10). The angiogenic prop- 
erties of both TNF-a and IL-8 can be favourable for the 
growth of the tumour as well as for growth of distant 
metastases (11-13). However, the cytokines IL-6 and IL-8 
attract other mononuclear cells that are known to interfere 
with tumour growth (8,9). In addition, IL-6 is well known 
as an inducer of the protective acute phase response of the 
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host (14). A former study of the authors’ group, showed the 
presence of immunohistochemical staining patterns for 
TNF-a, IL-6 and IL-8 and enhanced expression of both 
TNF receptors in tissue samples obtained from resection 
specimens of non-small cell lung carcinoma (NSCLC) 
patients (15). These data combined with the enhanced 
expression of the adhesion molecules E-selectin, intercellu- 
lar adhesion molecule (ICAM)-l and vascular cell adhesion 
molecule (VCAM)-1 (16) reflect the presence of a local 
inflammatory response around the tumour cells in NSCLC. 
The authors also observed the presence of a systemic 
inflammatory response in NSCLC. Enhanced levels of both 
soluble (s) TNF receptors, the acute-phase proteins 
C-reactive protein (CRP) and LPS-binding protein (LBP), 
and sICAM-1 were demonstrated in plasma of patients 
with NSCLC (7). The soluble forms of both TNF receptors, 
the adhesion molecules and both acute phase proteins are 
considered to reflect inflammatory activity (17-19). Meta- 
bolic disturbances were found to be related to the presence 
of these enhanced levels of inflammatory mediators in 
patients with NSCLC (7). The present data were supported 
by others who found a similar relationship between 
metabolic disturbances and inflammatory parameters in 
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TABLE 1. Characteristics of the study population 
NSCLC Control subjects 
(n=20) (n=9) 
Male/female 
Age (years) 
Years of smoking 
FEV, (%) 
IVC (%) 
Tumour stage (n) 
Stage I and II 
Stage IIIA 
Stage IIIB 
Stage IV 
1416 712 
63 z!z 2 55 f 3 
43 * 3 33-1-4 
88&5 95+4 
105 * 3 103 It 5 
12 
5 
1 
2 
Data are expressed as mean & standard error of the mean. 
No significant differences have been found between the lung 
cancer population and control subjects. FEV,, forced 
expiratory volume in 1 s; IVC, inspiratory vital capacity; 
n, number; NSCLC, non-small cell lung cancer. 
patients with pancreatic carcinoma and haematological 
malignancies (4-6). 
The present study investigated whether the inflammatory 
process in the interstitial compartment of the affected lung 
extends into the alveolar compartment of the lung in 
NSCLC. The bronchoalveolar lavage (BAL) is an import- 
ant tool to assess the inflammatory state in the alveolar 
compartment of the lung. During different acute inilam- 
matory reactions, cellular changes in BAL fluid (F) (influx 
of neutrophils or lymphocytes) occur and alveolar macro- 
phages (AM), the major cellular component of the alveolar 
compartment, can be activated (20). Besides these cellular 
changes, the presence of an inflammatory state in the 
alveolar compartment is reflected by increased levels of the 
pro-inflammatory cytokines TNF-a, IL-6 and IL-8 or sol- 
uble adhesion molecules in BALF, as has been demonstrated 
in several pulmonary diseases (21-27). 
The aim of the present study was to investigate whether 
the alveolar compartment was involved in the inflammatory 
response in NSCLC. To this end, the pro-inflammatory 
cytokines, both soluble TNF receptors and soluble 
adhesion molecules were assessed in BALF and the 
production of cytokines by AM was determined in vitro. 
BALF obtained from the tumour site was compared 
with BALF obtained from the contralateral lung as well 
as with BALF obtained from control subjects. 
Subjects and Methods 
PATIENTS AND CONTROL SUBJECTS 
The characteristics of the study population are shown in 
Table 1. Twenty patients with primary NSCLC (12 patients 
with squamous cell carcinoma and eight patients with 
adenocarcinoma) and nine control subjects were included in 
the study. All patients had histologically documented 
tumours. Fourteen tumours were located in the upper 
lobes, three tumours were located in the middle lobe or 
lingula and three tumours were located in the lower lobes. 
As a result of the research questions, all tumours were 
located peripherally in order to perform an adequate BAL. 
All patients and control subjects were current smokers 
(n=18) or had stopped smoking during the last 6 months 
(n=ll). The patients had not been treated with chemo- 
therapy, radiotherapy or with systemic or inhaled cortico- 
steroids. The new international staging system for lung 
cancer was used to assess tumour stage (28). Control 
subjects were selected out of the smoking patient popu- 
lation who underwent a bronchoscopy for several reasons, 
but finally no pathology was demonstrated. 
The study was approved by the medical ethical commit- 
tee of the University Hospital of Maastricht. Written 
informed consent was obtained from all patients and 
control subjects. 
BRONCHOALVEOLAR LAVAGE 
BAL was performed during fibre-optic bronchoscopy. After 
premeditation (atropine 0.5 mg i.m. and diazepam 10 mg 
p.o. 1 h before bronchoscopy) and local anaesthesia of the 
larynx and bronchial tree (lignocaine’ lo%), a flexible, 
fibre-optic bronchoscope was introduced and placed in 
wedge position in the segment with tumour localization as 
well as in either the lingula or the middle lobe of the 
contralateral lung. Positioning of the bronchoscope in 
respect to tumour localization was controlled by fluoros- 
copy during the endoscopic procedure. Accordingly, BAL 
was performed by standardized washing of these segments. 
Four aliquots of 50 ml ~ r sterile saline (0.9% NaCl) at 37°C 
were used for each lung. In control subjects, BAL was 
performed unilaterally either in the lingula or right middle 
lobe. The first aliquot of recovered BALF was discarded 
and the last three aliquots were pooled. BALF was col- 
lected in polypropylene tubes (Greiner, Alphen a/d Rijn, 
The Netherlands) and kept on ice in order to minimize AM 
adherence. Cytospin slides of BALF cells were stained 
with May-Griinwald-Giemsa (MGG; Merck, Darmstadt, 
Germany) for cell differentiation. At least 1000 cells were 
counted. Cytologic examination of the BALF revealed no 
malignant cells. Next, cells were separated from BALF by 
centrifugation at 500 x g for 5 min after cell differentiation. 
Cell-free BALF was filtered through a layer of gauze to 
remove mucus strands. BALF was concentrated by lyo- 
philization and resuspended in distilled water to 10% of 
the original volume before determinations and stored at 
- 70°C until analysis. No significant positive bacterial 
cultures were found in any of the BALF samples investi- 
gated. Blood was obtained by venepuncture and collected 
in evacuated blood collection tubes (Sherwood Medical, 
St Louis, MO, U.S.A.) containing Heparin@ (Leo 
Pharmaceutical Products B.V., Weesp, The Netherlands). 
ALVEOLAR MACROPHAGES CULTURE 
After centrifugation, cells obtained from BALF were 
washed twice and filtered through a modified transfusion 
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system (N.P.B.I., The Netherlands). Cells were cultured in 
medium consisting of RPM1 1640 (Gibco, Paisley, U.K.) 
supplemented with antibiotics and 10% bovine calf serum 
(Hyclone, Logan, UT, U.S.A.). Bovine calf serum was 
heated at 56°C for 30 min before storage at 4°C and 
contained ~5 pg ml- ’ endotoxin as determined in the 
Limulus assay (Coatest, Kabi Vitrum, Stockholm, Sweden). 
Cells, consisting for more than 90% of AM, were cultured 
at a number of 5-O x lo5 ml - r in 24-well plates (Costar, 
Cambridge, MA, U.S.A.) and stimulated in duplo with LPS 
(E. coli 055:B5, Sigma, St. Louis, MO, U.S.A.); in concen- 
trations of 0, lOngm-‘, lpgml-’ and 100pgml-‘. 
After 20 h of stimulation, which was found to be the 
optimum for TNF-a, IL-6 and IL-8 production by AM as 
determined (data not shown), plates were centrifuged at 
500 x g, supernatant was collected and stored at - 70°C 
until analysis. 
INFLAMMATORY MEDIATORS 
Inflammatory mediators were assessed in both plasma 
and BALF using sandwich ELISA as described previously 
(29-33). In short, the TNF-a ELISA consisted of 61E71 as 
coating mAb and polyclonal rabbit anti-human TNF-a 
Abs. TNF-a could ,be detected with a lower detection limit 
of 20 pg ml - r. For measurement of sTNF-R55 and sTNF- 
R75, MAbs MRl-1 and MR2-2 were used for coating, 
respectively. Specific biotin labelled polyclonal rabbit anti- 
human sTNF-R IgG were used as detector reagents. The 
detection limit of both assays was 50 pg ml - ‘. 
IL-6 was caught by mAb 5El and detected by polyclonal 
rabbit anti-human 11-6 Abs. IL-6 could be detected with 
a lower detection limit of 10 pg ml - ‘. The IL-8 ELISA 
consisted of HM5 as coating mAb and biotinylated poly- 
clonal rabbit anti-human IL-8 Abs. The detection limit of 
IL-8 was 20 pg ml - ‘. For sICAM-1 ELISA, mAb HM.2 
was used for coating. Biotinylated mAb HM.l was used 
for detection. The detection limit of the assay was 
400 pg ml- ‘. For SE-selectin ELISA, plates were coated 
with mAb ENAl and biotin labelled mAb ENA was used 
as detector reagent. Since binding of ENAl and ENA to 
SE-selectin is Ca-dependent, 4 mM Ca++ and 2.5 mM 
Mg++ were added to the buffers in this assay. The detection 
limit of the assay was 100 pg ml - ‘. 
Immunoassay plates (Nunc-Immuno Plate Maxisorp, 
Roskilde, Denmark) were used for the ELISA assays. 
Biotinylated samples were detected with streptavidin- 
peroxidase conjugate (Dako, Glostrup, Denmark), while 
peroxidase-conjugated goat anti-rabbit IgG (Jackson 
Immunoresearch, West Grove, PA, U.S.A.) was used in the 
TNF-a and IL-6 ELISA. TM3 (3,3’,5,5’-tetramethylbenzi- 
dine, Kirkegaard & Perry Lab., Gaithersburg, MD, U.S.A.) 
was used as a substrate. Photospectometry (450 nm) was 
performed using a micro ELISA autoreader. 
BIOCHEMICAL PARAMETERS 
Serum urea and albumin have been determined on a 
Synchron CX-7 analyser (Beckman Instruments Inc, 
U.S.A., California) using test kits from Beckman Instru- 
ments Inc. For the determination of urea in both serum and 
BALF, an enzymatic conductivity rate method was used. 
For the determination of serum albumin, the bromcresol 
purple method was used. In BALF, albumin was deter- 
mined on an Array 360 System for immunochemistry 
(CA, U.S.A.), using a micro-albumin method. BALF total 
protein was measured with the pyrgallol method described 
by Watanabe et al. (34). Lactate dehydrogenase (LDH) 
activity was measured by an enzymatic rate method, 
using pyruvate as a substrate. Alkaline phosphatase 
(ALP) was measured by an enzymatic rate method using 
p-nitrophenylphosphate as a substrate. 
STATISTICS 
Data are expressed as mean f standard error of the mean 
(SEM) and, if appropriate, as median with range. Groups 
were statistically compared using analysis of variance or the 
Mann-Whitney U-test. The BALFlblood ratios were calcu- 
lated for albumin and urea in order to get insight in possible 
leakage between the alveolar compartment and the blood 
compartment. BALFlblood ratios for albumin and urea 
were calculated as follows: BALFlblood ratio for 
albumin =[albumin level in BALFy[albumin level in blood]. 
The same calculation was used for urea. Probability values 
less than 0.05 were considered to be significant. The 
statistical analyses were performed using the SPSS/PC+ 4.0 
package (35). 
Results 
First the systemic and local inflammatory response were 
assessed in the study population. Thirteen out of the 20 
NSCLC patients demonstrated an acute phase response 
(CRP level: 20 & 18 ,ug ml - ‘, range 7-57 fig ml - ‘), while 
no enhanced levels of CRP were detected in control subjects 
(CRP ~5 pg ml- ‘). The mean values ( i SEM) of the other 
inflammatory mediators in plasma of the lung cancer 
patients compared to controls were as follows: sTNF-R55 
1.3 & 0.2 YS 1.1 & 0.4 ng ml - ’ (not significant), sTNF- 
R7.5 2.0 & 0.3 vs 1.3 f 0.4 ng ml-i (P<O.Ol), sICAM-1 
66.9 f 6.0 vs 40.3 f 5.4 ng ml - r (P<O.O5), sE-selectin 
29.1 f 3.0 vs 33.4 -+ 5.6 (not significant). 11-6 was not detect- 
able in controls and IL-6 and IL-8 were only present in very 
small amounts in plasma of the lung cancer patients. The 
local inflammatory response could be investigated in the 
resection materials of 12 out of the 20 NSCLC patients as 
described in previous studies. An accumulation of mono- 
nuclear cells around the tumour cells was demonstrated 
in all specimens investigated. These findings indicate the 
presence of a local inflammatory response. 
In order to investigate the inflammatory response in the 
alveolar compartment in NSCLC, the cellular profile of 
BALF was assessed (Table 2). The data show that the total 
cell count and the differential cell count did not show 
significant differences between the BALF obtained from 
patientssuffering from NSCLC and control subjects. In line 
with these data, also no differences in cellular profile 
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TABLE 2. Cellular profile of the bronchoalveolar lavage fluid in NSCLC and control subjects 
NSCLC patients (n=20) 
Tumour site Contralateral 
Control subjects 
(n=8) 
Recovery (ml) 60.3 xk4.5 71.6 rt 5.1 77.6 i 8.3 
Total cell count ( x lo4 ml) 33.61k 5.9 31.8 i 5.3 18.5 xt4.2 
AM (%) 89.3 f2.7 91.1 12.3 91.7rt 3.9 
PMN (%) 2.5 + 0.9 1.5sio.4 I.7 *to-L3 
Lymphocytes (%) 8.0 & 2.3 7.8 12.3 6.5 * 3.2 
Data are expressed as mean & standard error of the mean. AM, alveolar macrophages; PMN: 
polymorphonuclear neutrophils; NSCLC, non-small cell lung cancer. 
TABLE 3. Non-cellular constituents of the bronchoalveolar lavage fluid in NSCLC and controls 
NSCLC patients (n=20) 
Tumour site Contralateral 
Controls 
(n=9) 
Albumin (mg I- ‘) 
Total protein (mg I- ‘) 
Urea (mm01 I- ‘) 
BALF/blood ratio 
for albumin 
BALFlblood ratio 
for urea 
33.5&44-2 
27.03 (13G75.0) 
5OztlO 
40(10-180) 
0.46 f0.05 
0.50 (0~10-0~70) 
0.09% o-01 
0.07 (0~0%0~21) 
0.09fO.O 1 
0.08 (0.01-0.18) 
27.6& 3.6 
22.0 (8.0-58.0) 
40* 10 
30 (IO-SO) 
0.48 SO.04 
0.50 (0~10-0~90) 
0.07 *o-o1 
0.06 (0.02-0.15) 
0~09dc0~0 1 
0.08 (0.02-0.19) 
30.3 Ik4.5 
29.0 (11~0-59~0) 
4OztlO 
30(20-80) 
0.37 ho.07 
0.40 (0~10-0~70) 
0.08 ?cO~Ol 
0.07 (O-03-0.15) 
0.08 *0.02 
O-06 (0.02-0.19) 
Data are expressed as mean i standard error of the mean; the median is given with the range in 
parentheses. No significant differences were found between the different sites investigated. BALF, 
bronchoalveolar lavage fluid; NSCLC, non-small cell lung cancer. 
between the affected lung and the contralateral lung of the 
NSCLC patients were observed. In case of damage to the 
alveolo-capillary membrane and oedema, one would expect 
increased levels of the non-cellular constituents total pro- 
tein, albumin and urea in BALF. Equal levels of the 
non-cellular constituents were demonstrated in BALF 
obtained from the lung cancer population and from control 
subjects (Table 3). Moreover, the levels were also similar 
between the affected lung and the contralateral lung in 
NSCLC patients. In order to assess the degree of dilution of 
BALF, BALF/blood ratios for albumin and ureum were 
determined. The data showed that these ratios were similar 
for both the tumour lung and contralateral lung and for the 
lung cancer population and control subjects. No differences 
in degree of dilution could therefore be detected among the 
three groups. 
Next, the levels of inflammatory mediators in BALF of 
both NSCLC patients and control subjects were deter- 
mined. The data are summarized in Table 4. Comparable 
results were found for both soluble TNF receptors, 
sICAM- 1, SE-selectin and the pro-inflammatory cytokines 
IL- 6 and IL-8 between patients suffering from NSCLC 
and control subjects. TNF-a was not detectable in any of 
the BALF samples investigated (data not shown). Only 
small amounts of sTNF-R55, SE-selectin and IL-6 were 
present in BALF. The mean ievels were near the detection 
limit of the ELISA which explains the narrow range 
observed for these parameters. In accordance with 
other studies, larger ranges were detected for the other 
inflammatory mediators. In order to investigate whether 
tumour characteristics could influence levels of inflam- 
matory mediators in BALF, patients were divided accord- 
ing to tumour stage or histology of the tumour. These 
analyses revealed no differences in levels of inflammatory 
mediators (data not shown). 
The local inflammatory response was further investigated 
by measuring LDH and ALP in BALF as indicators of cell 
death and injury (36,37). Mean levels for LDH in the lung 
cancer population were 28 f 3 U I- ’ in the affected lung 
and 29 * 2 U I- i in the contralateral lung while mean level 
for LDH in control subjects was 31 * 4 U I- ’ (normal 
range IO-50 U 1~ ‘). ALP was neither detectable in BALF 
of patients suffering from NSCLC nor in BALF of control 
subjects (normal range O-25 U I- ‘). 
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TABLE 4. Inflammatory mediators in the bronchoalveolar lavage fluid 
NSCLC patients (n =20) 
Tumour site Contralateral Controls@ = 9) 
sTNF-R55 (ng ml ~ ‘) 0.08 x!z 0.02 0.08 f 0.02 0.07 zt 0.03 
0.04 (0~01-0~40) 0.04 (0.01-0.48) 0.03 (0.01-0.27) 
sTNF-R75 (ng ml - ‘) 0.37 It 0.07 0.30 f 0.05 0.21 It 0.05 
0.32 (O+-1.10) 0.26 (0.02-087) 0.11 (0.07-0.48) 
sICAM-1 (ng ml - ‘) 103.6 ZIZ 19.6 96.0 f 19.4 120.3 f 44.0 
66.9 (19.0-326.0) 87.0 (20.66410.2) 94.0 (28.0462.0) 
SE-selectin (ng ml - ‘) 0.12 * 0.01 0.10 f 0.10 0.10 Xt 0.02 
0.10 (0.10-0.31) 0.10 (0.10-0.14) 0.10 (0.10-0.25) 
IL-6 (ng ml - ‘) 0.04 + 0.01 0.04 f 0.01 0.04 It 0.01 
0.05 (0.01-0.13) 0.03 (0~01~0~11) 0.04 (0.02-0.08) 
IL-8 (ng ml - ‘) 0.36 f 0.16 0.14 zk 0.03 0.26 & 0.11 
0.15 (0.01-3.1) 0.11 (0.02-0.39) 0.11 (0.01-0.93) 
Data are expressed as mean & standard error of the mean; the median is given with the range in 
parentheses. No significant differences were found between the different sites investigated. s, soluble; 
TNF-R55, TNF receptor 55; ICAM-1, intercellular adhesion molecule-l; NSCLC, non-small cell 
lung cancer. 
Finally, the ability of AM to produce cytokines in vitro 
was determined. AM were obtained from both the affected 
and the contralateral lung of the lung cancer population 
and were activated in culture with different concentrations 
of LPS. Comparable results were demonstrated in cytokine 
production between AM obtained from the tumour lung 
and AM obtained from the contralateral lung either with or 
without stimulation of LPS (Fig. 1). 
Discussion 
Nowadays, BAL is a widely accepted tool for both diag- 
nostic and research purposes to investigate the alveolar 
compartment. Enhanced levels of inflammatory mediators 
in BALF reflect the inflammatory state in the alveolar 
compartment of several pulmonary diseases such as pul- 
monary sarcoidosis, idiopathic pulmonary fibrosis, HIV- 
infected patients, chronic obstructive pulmonary disease, 
adult respiratory distress syndrome and pneumoconiosis 
(21-27). Previously, the authors demonstrated increased 
plasma levels of inflammatory mediators in NSCLC 
patients (7). In addition, a local inflammatory response 
around the tumour cells was demonstrated in tissue samples 
obtained from resection specimens of NSCLC patients 
(15,16). In the present study, however, the levels of inflam- 
matory mediators in BALF of NSCLC patients were com- 
parable with those in control subjects. In addition, no 
differences in levels of inflammatory mediators in BALF 
and cytokine profiles of AM were found between the 
affected and the contralateral lung in patients with NSCLC. 
The present data are in contrast with Arias-Diaz et al. (38) 
who found increased levels of TNF-a and IL-6 in BALF 
obtained from 22 patients with bronchogenic squamous 
carcinoma. Plumb et al., however, supported the present 
. 
data (39); they reported no differences in cytokine profiles 
(IL-l and TNF-a) in BALF between lung cancer patients 
and control subjects. Further, the present authors observed 
that the levels of the chemotactic cytokines IL-6 and IL-8 in 
BALF were similar between the NSCLC patients and 
control subjects. Since the expression of both TNF recep- 
tors on NSCLC cells was enhanced (15), both sTNF 
receptors were determined in BALF. Comparable results 
for both sTNF receptors were demonstrated in BALF 
obtained from the tumour lung and the contralateral lung 
as well as from the lung of control subjects. In addition, the 
soluble adhesion molecules E-selectin and ICAM- in 
BALF were determined. An enhanced expression of these 
adhesion molecules was observed in NSCLC (16). The 
soluble forms of these adhesion molecules are considered to 
represent inflammatory activity as well (19). No differences 
were found for SE-selectin and sICAM-1 in BALF between 
NSCLC and controls either. 
The present study did not demonstrate an enhanced 
inflammatory state in the alveolar compartment of NSCLC 
patients. The data suggest that no damage of the alveolar 
membrane was present and, as a consequence, no leakage 
of inflammatory mediators occurred. This hypothesis is 
supported by the absence of signs of cell damage in BALF; 
no enhanced levels of LDH or ALP, known as parameters 
for cell damage or cell death, were detected. Comparable 
results were found in cellular distribution of BALF 
samples obtained from the three groups. Moreover, no 
malignant cells were found in BALF obtained from the 
tumour site. 
Another explanation for the absence of an inflammatory 
state in the alveolar compartment might be that the tumour 
itself or the infiltrating cells produce immunosuppressive 
molecules that affect the production of cytokines by AM in 
the alveolar compartment. 
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FIG. 1. Stimulation experiments of alveolar macrophages 
subdivided according to cytokine production. (a) TNF-a 
production by alveolar macrophages after stimulation 
with 0, lOngml-i, lpgml-’ and lOOpgml-’ LPS. 
(b) IL-6 production by alveolar macrophages after 
stimulation with LPS. (c) IL-8 production by alveolar 
macrophages after stimulation with LPS. Solid bars, 
tumour site; open bars, contralateral site. Results are 
expressed as mean + standard error of the mean. 
1 
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Immunosuppressive molecules such as IL-lo, nitric 
oxide, prostaglandin E, and sTNF-receptors are produced 
by tumour cells and macrophages in the environment of the 
tumour (4046). TNF receptors can have an immunol 
suppressive function by binding to biologically active 
TNF-a. However, the authors observed an enhanced 
expression of both TNF receptors in the interstitial com- 
partment, but not in the alveolar compartment. Increased 
levels of nitrite/nitrate and prostaglandin E, have been 
demonstrated in BALF of patients with primary lung 
cancer (38,46). 
Beside these possible explanations for the absence of an 
enhanced inflammatory state (as reflected by BALF analy- 
sis) in the alveolar compartment next to the tumour, 
smoking behavior needs to be taken into account as well. 
Smoking can affect the total and differential cell count of 
the BALF and changes the viability and cytokine produc- 
tion of AM. Reduced production of TNF-a, IL-l/3 and IL-6 
by AM has been demonstrated in smokers by several 
authors (4749) 49. In the present study, all patients and 
control subjects were smokers or stopped smoking recently, 
and no significant differences were detected in smoking 
behaviour between patients suffering from NSCLC and 
control subjects. Although possible differences in BALF 
analysis could be hypothesized in non-smoking patients, the 
dominant role of cigarette smoking in lung cancer causation 
evidenced the study of inflammatory changes in smoking or 
ex-smoking lung cancer patients. 
In conclusion, comparable results in levels of inflamma- 
tory mediators in BALF were found between NSCLC 
patients and control subjects. In addition, no differences in 
cytokine profiles of AM were found between the affected 
lung and the contralateral lung in patients with NSCLC. 
Although the BAL is a useful tool in the diagnostic 
procedure for NSCLC, the present findings suggest that 
BAL does not reflect the enhanced inflammatory state, as 
reported in plasma and in the interstitial compartment 
around the tumour cells in NSCLC. 
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